Almirall Partners with CrystalO for AI-Driven Dermatology Drug Discovery
Event summary
- Almirall and CrystalO have entered a collaboration to discover and develop novel small-molecule drugs for medical dermatology.
- CrystalO will leverage its AI- and structure-based drug discovery platform, while Almirall holds exclusive global rights outside mainland China.
- The deal includes an upfront payment to CrystalO, plus success-based milestone payments and tiered royalties.
- Almirall has invested over €1 billion in dermatology R&D over the last decade, with 12.5% of 2025 net sales (€1114.5M) allocated to R&D.
The big picture
This collaboration underscores Almirall's commitment to innovation in dermatology, particularly through external partnerships that combine AI-driven drug discovery with clinical development expertise. The deal reflects a broader industry trend of biopharmaceutical companies leveraging cutting-edge technologies to accelerate therapeutic breakthroughs while managing R&D costs efficiently.
What we're watching
- Execution Risk
- How CrystalO's AI-driven platform will perform in advancing dermatology drug candidates through proof-of-concept testing.
- Market Expansion
- Whether Almirall can leverage this partnership to strengthen its position in the global medical dermatology market.
- Regulatory Dynamics
- The pace at which regulatory approvals for novel ion channel-targeted therapies will progress in key markets.